Indivior (LON:INDV) Earns “Buy” Rating from Jefferies Financial Group

Jefferies Financial Group reissued their buy rating on shares of Indivior (LON:INDV) in a report published on Tuesday, Marketbeat.com reports. They currently have a GBX 1,800 ($22.50) price objective on the specialty pharmaceutical company’s stock.

Separately, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 1,500 ($18.75) price target on shares of Indivior in a research note on Thursday, September 5th.

Indivior Trading Down 3.4 %

LON:INDV opened at GBX 913.50 ($11.42) on Tuesday. The company has a debt-to-equity ratio of 2,790.00, a quick ratio of 1.52 and a current ratio of 0.85. The company has a market capitalization of £1.17 billion, a P/E ratio of -1,141.88, a P/E/G ratio of -5.57 and a beta of 0.19. The stock’s 50 day moving average price is GBX 775.71 and its 200 day moving average price is GBX 917.47. Indivior has a 52 week low of GBX 554.50 ($6.93) and a 52 week high of GBX 1,770 ($22.12).

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.